Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.74 and traded as high as $2.93. Acasti Pharma shares last traded at $2.93, with a volume of 2,465 shares.
Wall Street Analyst Weigh In
Separately, Craig Hallum began coverage on shares of Acasti Pharma in a research note on Wednesday, February 7th. They issued a “buy” rating and a $6.00 target price on the stock.
Check Out Our Latest Stock Report on ACST
Acasti Pharma Stock Down 1.0 %
Acasti Pharma (NASDAQ:ACST – Get Free Report) last released its earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. On average, equities research analysts expect that Acasti Pharma Inc. will post -1.44 earnings per share for the current fiscal year.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Articles
- Five stocks we like better than Acasti Pharma
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 4/22 – 4/26
- What Are Growth Stocks and Investing in Them
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
